{"id":58649,"date":"2026-03-03T13:44:39","date_gmt":"2026-03-03T05:44:39","guid":{"rendered":"https:\/\/flcube.com\/?p=58649"},"modified":"2026-03-03T13:44:40","modified_gmt":"2026-03-03T05:44:40","slug":"revir-therapeutics-doses-first-patient-in-rtx-117-trial-chinas-first-ai-rna-small-molecule-enters-clinic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58649","title":{"rendered":"ReviR Therapeutics Doses First Patient in RTX-117 Trial \u2013 China’s First “AI + RNA” Small Molecule Enters Clinic"},"content":{"rendered":"\n

ReviR Therapeutics<\/strong>, a clinical\u2011stage biotech incubated by XtalPi (HKG:\u202f2228<\/a>)<\/strong>, announced first subject dosing<\/strong> in a clinical trial for RTX-117<\/strong>, its Category\u202f1 drug candidate<\/strong>. This milestone marks the official entry into clinical development<\/strong> of the first “AI + RNA” small molecule drug in China<\/strong>, discovered through the XtalPi\u2011ReviR collaboration<\/strong>.<\/p>\n\n\n\n

Clinical Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>ReviR Therapeutics (XtalPi incubated)<\/td><\/tr>
Product<\/strong><\/td>RTX-117<\/td><\/tr>
Drug Class<\/strong><\/td>Category\u202f1 innovative drug; “AI + RNA” small molecule<\/td><\/tr>
Innovation Status<\/strong><\/td>First of its kind in China<\/strong> to enter clinics<\/td><\/tr>
Discovery Platform<\/strong><\/td>XtalPi AI + ReviR VoyageR RNA biology platform<\/td><\/tr>
Clinical Stage<\/strong><\/td>First patient dosed; Phase I initiated<\/td><\/tr>
Target Indications<\/strong><\/td>Charcot\u2011Marie\u2011Tooth disease (CMT); vanishing white matter leukoencephalopathy (VWM)<\/td><\/tr>
Market Potential<\/strong><\/td>>\u202fUSD\u202f10\u202fbillion global addressable market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Platform \u2013 “AI + RNA”<\/h2>\n\n\n\n
Component<\/th>Function<\/th><\/tr><\/thead>
XtalPi AI<\/strong><\/td>Machine learning\u2011driven small molecule design and optimization<\/td><\/tr>
ReviR VoyageR<\/strong><\/td>Proprietary RNA biology platform targeting disease\u2011causing RNA structures<\/td><\/tr>
Combined Approach<\/strong><\/td>AI\u2011enabled discovery of RNA\u2011targeting small molecules with high specificity<\/td><\/tr>
Therapeutic Advantage<\/strong><\/td>Disease\u2011modifying potential vs. symptomatic management in neurological diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Diseases<\/h2>\n\n\n\n
Disease<\/th>Patient Population<\/th>Unmet Need<\/th><\/tr><\/thead>
Charcot\u2011Marie\u2011Tooth (CMT)<\/strong><\/td>Most common inherited neurological disorder (~\u202f3\u202fmillion globally)<\/td>No disease\u2011modifying therapies; progressive disability<\/td><\/tr>
Vanishing White Matter (VWM)<\/strong><\/td>Rare leukoencephalopathy affecting children<\/td>Fatal neurodegenerative disease; no approved treatments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n